Clinical trials: Retina Patients
OAG - Open-Angle Glaucoma, OHT - Ocular Hypertension
Effects of Netarsudil and Timolol on Retinal Blood Vessel Density and Visual Acuity
The purpose of this research study is to compare the effect of Netarsudil and Timolol on eye pressure and blood vessels of the back of the eye.
- Trial name
- NCT04064918
- Testing
- Netarsudil 0.02% QD, Timolol maleate 0.5% BID
- Volunteers
- healthy volunteers welcome
- Sponsor
- University of California, San Diego
Diabetes, Diabetic Retinopathy
Improve Timely Referral Flow and Compliance of Diabetic Retinopathy Patients
An effective referral system helps to ensure a close relationship between all levels of the health system and ensures clients receive optimum care at the appropriate level and at affordable cost, and hospital facilities are used…
- Trial name
- NCT04834648
- Testing
- Structured Counseling
- Where
- Nepal
- Volunteers
- 150 people
- Sponsor
- Seva Foundation
Age-Related Macular Degeneration, Wet Age-related Macular Degeneration
User-centric Study of Patients' Receptiveness Towards the Web-based Automated Vision Impairment Gaze-tracking Analysis Systems
Age-Related Macular Degeneration (AMD) is the leading cause of central vision loss among older adults worldwide. Patients with AMD often require frequent monitoring of visual function and disease progression, typically through…
- Trial name
- AVIGA-SURVEY (NCT07338513)
- Where
- Singapore
- Volunteers
- 30 people
- Sponsor
- Tan Tock Seng Hospital
Macular Degeneration
Macular EpiRetinal Brachytherapy Versus Lucentis® Only Treatment (MERLOT)
Wet age-related macular degeneration is the most common cause of blind registration in the United Kingdom (UK). Standard treatment involves regular eye injections of a drug called ranibizumab (Lucentis).
- Trial name
- MERLOT (NCT01006538)
- Testing
- Epimacular Brachytherapy, Ranibizumab
- Where
- 24 sites in United Kingdom
- Volunteers
- 363 people
- Sponsor
- King's College Hospital NHS Trust
Retinitis Pigmentosa
A Study of Encapsulated Cell Technology (ECT) Implant for Patients With Late Stage Retinitis Pigmentosa
The purpose of this study is to look at the safety and effectiveness of CNTF implants on vision in persons with retinitis pigmentosa, Usher type II \& III, and Choroideremia.
- Trial name
- NCT00447993
- Testing
- Low Dose NT-501, High Dose NT-501
- Where
- 11 sites in United States
- Volunteers
- 67 people
- Sponsor
- Neurotech Pharmaceuticals
Choroidal Neovascularization in Angioid Streaks
Phase II Study Evaluating the Efficacy of Aflibercept for the Treatment of Choroidal Neovascularization in Angioid Streaks in Young Patients (ASTRID).
Angioid streaks are rare lesions associated to retinal pigment epithelium degenerations. They can be caused by general diseases as pseudoxanthoma elasticum, Paget's disease or drepanocytosis.
- Trial name
- ASTRID (NCT02573038)
- Testing
- Aflibercept
- Sponsor
- Hospices Civils de Lyon
Diabetic Retinopathy
Non-proliferative Diabetic Retinopathy Treated With Runcaciguat
This Phase 2 study is conducted to investigate the safety and efficacy of runcaciguat in the treatment of diabetic retinopathy. To assess efficacy, the retinal morphology will be investigated by 7-field color fundus photography…
- Trial name
- NEON-NPDR (NCT04722991)
- Testing
- Runcaciguat (BAY1101042)
- Where
- 55 sites in United States, Bulgaria and 12 more
- Volunteers
- 109 people
- Sponsor
- Bayer
Diabetic Retinopathy
A Study That Uses Data From Routine Eye Examinations of Patients Participating in Studies FIDELIO-DKD and FIGARO-DKD to Explore Whether Finerenone Can Delay the Progression of a Diabetes Complication That Affects the Eyes (Diabetic Retinopathy ,DR)
Diabetic retinopathy (DR) is a diabetes complication caused by damage to the small blood vessels inside the retina at the back of the eye. Diabetic retinopathy may cause mild vision problems or eventually blindness.
- Trial name
- ReFineDR (NCT04477707)
- Testing
- Finerenone (BAY94-8862)
- Where
- 62 sites in United States, Argentina and 13 more
- Volunteers
- 206 people
- Sponsor
- Bayer
Diabetic Retinopathy Visually Threatening
Internal Limiting Membrane Peeling in Proliferative Diabetic Retinopathy
Subject/Participant Groups: Study Group: Subjects undergo internal limiting membrane (ILM) peeling during vitrectomy for the indication of tractional retinal detachment Control Group: Subjects do not undergo ILM peeling during…
- Trial name
- NCT04380064
- Testing
- ILM Peeling, No ILM Peeling
- Where
- Mexico
- Volunteers
- 200 people
- Sponsor
- Rush Eye Associates
Retinal Vein Occlusion
Vitreous Level Of Tumor Necrosis Factor Alpha In Patients With Retinal Vein Occlusion
To assess the levels of TNF- α in vitreous samples of patients with retinal vein occlusion prior to administration of intravitreal anti-VEGF and compare them to levels in vitreous samples of normal subjects so as to investigate…
- Trial name
- NCT05532475
- Testing
- measurement of vitreous level of tumor necrosis factor alpha
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Kasr El Aini Hospital
Diabetic Macular Edema
A Study of the Safety and Tolerability of Intravitreal LKA651 in Patients With Diabetic Macular Edema
The purpose of this study is to evaluate the initial safety of intravitreal (IVT) LKA651 and potential for use alone or in combination with Ranibizumab ophthalmic solution (Lucentis®) for the treatment of Diabetic Macular Edema…
- Trial name
- NCT02281292
- Testing
- LKA651 ophthalmic solution, Ranibizumab ophthalmic solution
- Sponsor
- Alcon Research
Diabetic Retinopathy
Treatment for Completers of the Study B7A-MC-MBCM
To provide ruboxistaurin treatment to patients who completed the B7A-MC-MBCM study (NCT00604383), and who are felt by the investigator to have the potential to benefit from the ruboxistaurin treatment.
- Trial name
- NCT00266695
- Testing
- Ruboxistaurin
- Where
- 29 sites in United States
- Volunteers
- 203 people
- Sponsor
- Chromaderm, Inc.
Age-Related Macular Degeneration, Nonexudative Age-related Macular Degeneration
Transpalpebral Microcurrent Stimulation for the Improvement of Visual Acuity in Patients With Macular Degeneration
The goal of this clinical trial is to evaluate the effectiveness of transpalpebral microcurrent stimulation as a therapy for dry age-related macular degeneration.
- Trial name
- NCT05703867
- Testing
- Active microcurrent therapy
- Volunteers
- 404 people
- Sponsor
- Jarding, John, OD
Stargardt's Disease
Phase I/IIA Study of SAR422459 in Participants With Stargardt's Macular Degeneration
Primary Objective: To assess the safety and tolerability of ascending doses of SAR422459 in participants with Stargardt's Macular Degeneration (SMD). Secondary Objective: To evaluate for possible biological activity of SAR422459.
- Trial name
- NCT01367444
- Testing
- SAR422459
- Where
- 5 sites in United States, France
- Volunteers
- 27 people
- Sponsor
- Sanofi
Alcohol Use Disorder, Retinal Dystrophies
The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration
Oral disulfiram (Antabuse®) has been shown to improve image-forming vision in animal models with retinal degeneration due to its ability to decrease Retinoic Acid synthesis and consequently reduce hyperactivity in the inner…
- Conditions
- Alcohol Use Disorder, Retinal Dystrophies, Age-Related Macular Degeneration, Retinitis Pigmentosa
- Trial name
- NCT06319872
- Testing
- Oral disulfiram
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Rochester
Diabetic Retinopathy, Glaucoma
AI for the Detection of Retinal Disease and Glaucoma in Patients With Diabetes Mellitus in Primary Care
Background: Diabetic retinopathy (DR) is one of the most important causes of blindness worldwide, especially in developed countries.
- Conditions
- Diabetic Retinopathy, Glaucoma, Age-Related Macular Degeneration, Choroidal Nevus
- Trial name
- NCT04132401
- Testing
- algorithm
- Where
- Spain
- Volunteers
- 902 people
- Sponsor
- Fundacio d'Investigacio en Atencio Primaria Jordi Gol i Gurina
Brain and Central Nervous System Tumors, Intraocular Melanoma
Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer
RATIONALE: Radiolabeled monoclonal antibodies, such as iodine I 131 monoclonal antibody 3F8, can find tumor cells and carry tumor-killing substances to them without harming normal cells.
- Conditions
- Brain and Central Nervous System Tumors, Intraocular Melanoma, Lung Cancer, Melanoma (Skin)
- Trial name
- NCT00445965
- Testing
- DNA analysis, immunologic technique, pharmacological study
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Retinal Disease
Hematopoietic Stem Cell Transplantation in Autoimmune-Related Retinopathy(ARRON)
ARRON is a disease believed to be due to immune cells, cells which normally protect the body, but are now attacking the tissue in the retina and/or optic nerve.
- Trial name
- NCT00278486
- Testing
- Hematopoietic stem cell transplantation.
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Richard Burt, MD
Age-Related Macular Degeneration
Safety and Efficacy Study of OpRegen for Treatment of Advanced Dry-Form Age-Related Macular Degeneration
The main objective of the study is evaluation of the safety and tolerability of OpRegen - Human embryonic stem cell-derived retinal pigment epithelial (RPE) cells.
- Trial name
- NCT02286089
- Testing
- OpRegen
- Where
- 7 sites in United States, Israel
- Volunteers
- 24 people
- Sponsor
- Hoffmann-La Roche
Geographic Atrophy
ONL1204 Ophthalmic Solution in Patients With Geographic Atrophy Associated With Age-related Macular Degeneration
The purpose of this study is to evaluate the safety and tolerability of intravitreal injection of ONL1204 Ophthalmic Solution in patients with geographic atrophy associated with AMD.
- Trial name
- NCT04744662
- Testing
- ONL1204 Ophthalmic solution
- Where
- 8 sites in Australia, New Zealand
- Volunteers
- 28 people
- Sponsor
- ONL Therapeutics